Llwytho...
FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII
Replacement therapy with factor VIII (FVIII) is used in patients with hemophilia A for treatment of bleeding episodes or for prophylaxis. A common and serious problem with this therapy is the patient’s immune response to FVIII, because of a lack of tolerance, leading to the formation of inhibitory a...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Blood |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
American Society of Hematology
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5234219/ https://ncbi.nlm.nih.gov/pubmed/28064157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-07-727834 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|